Goldman Sachs Downgrades Validus Holdings (VR) to Neutral, Removes from Conviction Buy List
Tweet
Share
E-mailGet Alerts VR Hot Sheet
Price: $25.61 --0%
Rating Summary:
5 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 3 | New: 2
Rating Summary:
5 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 3 | New: 2
Join SI Premium – FREE
Goldman Sachs downgraded Validus Holdings (NYSE: VR) from Conviction Buy to Neutral with a price target of $40.00 (from $43.00) after 4Q12 earnings and a reduction in out-year estimates.
"We expect VR to be in a "holding pattern" as premiums are unlikely to pick up until the company tests midyear renewals and we expect capital deployment could be slow until then."
The firm raised FY12 EPS from $3.16 to $3.26, but lowered FY13 from $4.80 to $4.68 and FY14 from $5.35 to $5.05.
For an analyst ratings summary and ratings history on Validus Holdings click here. For more ratings news on Validus Holdings click here.
Shares of Validus Holdings closed at $36.60 yesterday.
"We expect VR to be in a "holding pattern" as premiums are unlikely to pick up until the company tests midyear renewals and we expect capital deployment could be slow until then."
The firm raised FY12 EPS from $3.16 to $3.26, but lowered FY13 from $4.80 to $4.68 and FY14 from $5.35 to $5.05.
For an analyst ratings summary and ratings history on Validus Holdings click here. For more ratings news on Validus Holdings click here.
Shares of Validus Holdings closed at $36.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loop Capital Starts MongoDB (MDB) at Buy, '2H Ramp Ahead'
- JPMorgan Upgrades TMBThanachart Bank PCL (TTB:TB) to Overweight
- Jefferies Upgrades Medpace (MEDP) to Buy
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, DowngradesRelated Entities
Goldman Sachs Conviction Buy List, Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
